- Bayer Group
- About Bayer
- Mission & Values
- Strategic Alignment
- Outlook and Targets
- Opportunity and Risk Report
- Corporate Governance
- Articles of Incorporation
- Board of Management
- Supervisory Board
- Sustainability and Commitment
- Listing and Key Figures
- Share Price
- Stockholders' Portal
- Ownership Structure
- Stock Programs
- Stock History
- Annual Stockholders’ Meeting 2017
- Live Events
- Investor Conferences
- Stockholders' Meeting
- Press Conferences
- Other Presentations
- Inside Information
- Investor News
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. A growing and aging world population requires an adequate supply of food and improved medical care. Our research and development activities are therefore focused on improving people’s quality of life by preventing, alleviating and treating diseases. At the same time, we are making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials. Our understanding of the biochemical processes in living organisms helps us address these demanding challenges.
Our goal is to achieve and maintain leadership positions in our markets. In this way we create value for our customers, stockholders and employees, at the same time strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. We also respect the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our mission – Bayer: Science for a Better Life.
Published on February 22, 2017 in the Annual Report 2016:
|€ million||€ million||in %|
|EBITDA before special items1||10,256||11,302||+10.2|
|EBITDA margin before special items1||22.3 %||24.2 %|
|EBIT before special items1||7,060||8,130||+15.2|
|Income before income taxes||5,236||5,887||+12.4|
|Net income (from continuing and discontinued operations)||4,110||4,531||+10.2|
|Earnings per share (from continuing and discontinued operations) (€)1||4.97||5.44||+9.5|
|Core earnings per share (from continuing operations) (€)1||6.82||7.32||+7.3|
|Net cash provided by operating activities (from continuing and discontinued operations)||6,890||9,089||+31.9|
|Net financial debt||17,449||11,778||-32.5|
|Capital expenditures as per segment table||2,511||2,578||+2.7|
|€ million||€ million||in %|
|Total dividend payment||2,067||2,233||+8.0|
|Dividend per share (€)||2.50||2.70||+8.0|
|Number of employees2 (Dec. 31)||116,600||115,200||-1.2|
|Personnel expenses (including pension expenses) (€ million)||11,176||11,357||+1.6|
|Proportion of women in senior management (%)||28||29|
|Proportion of employees with health insurance (%)||96||98|
|Fluctuation (voluntary / total) (%)||5.0 / 13.9||4.6 / 12.3|
|Hours of vocational and ongoing training per employee||20.0||22.1||+10.5|
2015 figures restated; figures for 2012–2014 as last reported
1 For definitions of the indicators see Chapter “Alternative Performance Measures Used by the Bayer Group.”
2 Employees calculated as full-time equivalents (FTEs)
2016 Key Data by Segment
Current Investor News
Not intended for U.S. and UK Media
Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer
Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States for patients with HCC more
The capital stock of Bayer AG, amounting to Euro 2,116,986,388.48, is divided into 826,947,808 no-par registered shares.The capital stock underlying the no-par value registered shares is evidenced by permanent global certificates deposited with Clearstream Banking AG, Frankfurt am Main, Germany. The Company’s shareholders have ownership in these certificates in proportion to their respective holdings.The current value of one share - the share price - is determined by the company's total value on the stock market (market capitalization) and the number of shares in circulation.
|Security Identification No.|
|Bloomberg||Xetra ®||BAYN GY|
|Frankfurter Wertpapierbörse||BAYN GF|
Bayer has a significant weighting in virtually all the major stock indices in line with its high market capitalization and share turnover.
Bayer stock is listed on all the German stock exchanges.
Information about the dividend for fiscal 2016
Conforming to the proposal of the Board of Management and the Supervisory Board, the Annual Stockholders’ Meeting on April 28, 2017 passed the resolution to pay a dividend for fiscal 2016 of EUR 2.70 per share. The resulting payout ratio of 37 percent calculated on core earnings per share (see Annual Report 2016, Chapter 2.2.1 of the Combined Management Report) is within our target corridor of 30 percent to 40 percent.
The dividend yield calculated on the share price of €99.13 at year end 2016 amounts to 2.7 percent and the total dividend payment to €2,233 million.
Stock ownership by region
Our ownership structure shows the international distribution of our capital stock. The highest proportion of our outstanding shares, almost 29 percent, is held by investors in the United States and Canada, followed by Germany with 22 percent. From a regional perspective, Bayer has a stable ownership structure that has altered only slightly in recent years.
Ownership Structure by Country
Bayer is currently rated as follows:
|Rating agency||Long-term rating||Short-term rating|
|S&P Global Ratings||A-||A-2|
Recently, the rating agencies took the following rating actions:
May 20, 2016: S&P Global Ratings placed 'A-/A-2' ratings for Bayer on CreditWatch with negative outlook.
June 22, 2017: S&P Global Ratings affirms ‘A-2’ short-term rating, removing its CreditWatch for it.
May 24, 2016: Moody’s placed Bayer’s A3/P-2 ratings under review for downgrade.
(published on July 27, 2017 in the Interim Report Second Quarter 2017)
Due to the current business and currency development, we are adjusting our forecast for the fiscal year 2017.
The forecast for the second half is based on the exchange rates as of June 30, 2017, including a rate of US$1.14 (previously: US$1.07) to the euro. A 1% appreciation (depreciation) of the euro against all other currencies would decrease (increase) sales on an annual basis by €300 million and EBITDA before special items by €80 million.
This results in the following changes overall for the Bayer Group: Sales are now expected to increase to more than €49 billion (previously: around €51 billion). This now corresponds to a mid-single-digit (previously: mid- to high-single-digit) percentage increase on a currency- and portfolio-adjusted basis. EBITDA before special items is now targeted to increase by a high-single-digit percentage (previously: low-teens percentage). We now aim to grow core earnings per share from continuing operations by a low- to mid-single-digit percentage (previously: mid- to high-single-digit percentage). Here it must be noted that Bayer’s interest in Covestro amounts to only 41% as of June 2017 (previously: 53%). Excluding capital and portfolio measures, net financial debt is targeted to be around €7 billion at the end of 2017 (previously: around €8 billion).
We are now budgeting for sales of between €35 billion and €36 billion (previously: approximately €37 billion) for our Life Science businesses. This corresponds to a low-single-digit percentage (previously: mid-single-digit percentage) increase on a currency- and portfolio-adjusted basis. We expect EBITDA before special items to come in slightly above the level of the previous year (previously: rise by a mid- to high-single-digit percentage).
Despite negative currency development, we confirm the forecast we published in February for Pharmaceuticals and continue to expect sales of more than €17 billion. This corresponds to a mid-single-digit percentage increase on a currency- and portfolio-adjusted basis. As before, we plan to raise sales of our key growth products to more than €6 billion. We continue to expect a high-single-digit percentage increase in EBITDA before special items. There is no change in our expectation of further improving the EBITDA margin before special items.
For Consumer Health, we forecast a weak second half of the year and now expect to generate full-year sales of about €6 billion (previously: more than €6 billion). This would be in line with the prior-year level on both a reported and a currency- and portfolio-adjusted basis (previously: low- to mid-single-digit percentage increase on a currency- and portfolio-adjusted basis). We now expect EBITDA before special items to decline by a high-single-digit percentage (previously: increase by a low- to mid-single-digit percentage).
We are now budgeting for sales of below €10 billion (previously: more than €10 billion) for Crop Science. This corresponds low-single-digit-percentage decline on a currency- and portfolio-adjusted basis (previously: low-single-digit percentage increase). We now expect EBITDA before special items to decline by a mid-teens percentage (previously: at the prior-year level).
We confirm the forecasts published in February and April 2017 for Animal Health, the Reconciliation and Covestro. This also applies to the forecasts for the other key data.
This fact sheet may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
|Bayer Investor Relations|
Head of Investor Relations
|Dr. Jürgen Beunink|
|Peter Dahlhoff |
|Prof. Dr. Olaf Weber |